AzaSite®
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout AzaSite®
AzaSite® is a approved stage product being developed by Merck for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00629980. Target conditions include Blepharitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00656539 | Approved | Completed |
| NCT00629941 | Approved | Completed |
| NCT00629590 | Approved | Completed |
| NCT00629980 | Approved | Completed |
Competing Products
15 competing products in Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 80 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 3 | 72 |
| TP-03, 0.25% + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2/3 | 60 |
| Lotilaner + Vehicle Control | LianBio | Phase 3 | 69 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone | Sun Pharmaceutical | Phase 3 | 77 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| Azithromycin ophthalmic solution, 1% + Vehicle | Merck | Phase 2 | 52 |
| Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment | Viatris | Phase 3 | 74 |
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 49 |
| KPI-121 + Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |